Skip to main content
RYTM
NASDAQ Life Sciences

Setmelanotide 3期试验达到主要终点，BMI降低16.4%；PDUFA日期定为3月20日

feedReported by Reuters
Sentiment info
Positive
Importance info
9
Price
$92.66
Mkt Cap
$6.332B
52W Low
$45.905
52W High
$122.2
Market data snapshot near publication time

summarizeSummary

Rhythm Pharmaceuticals宣布了Setmelanotide在获得性下丘脑性肥胖患者中的额外阳性3期数据，达到主要终点，BMI显著降低16.4%。同时，公司确认了该药物的PDUFA目标日期为2026年3月20日。这一消息具有高度的材料性，因为阳性3期结果，特别是达到主要终点并具有强大的临床结果，显著降低了该药物的监管风险并提高了其商业前景。确认的PDUFA日期为潜在的FDA批准决定提供了明确的、近期的催化剂，预计将推动大量的股票波动。交易者现在将密切监视FDA在指定的PDUFA日期前的决定。

在该公告发布时，RYTM的交易价格为$92.66，交易所为NASDAQ，所属行业为Life Sciences，市值约为$63.3亿。 52周交易区间为$45.91至$122.20。 这则新闻被评估为积极市场情绪，重要性评分为9/10。 来源：Reuters。

show_chartPrice Chart

Share this article

Copied!

feed RYTM - Latest Insights

RYTM
Apr 03, 2026, 3:06 PM EDT
Filing Type: 8-K
Importance Score:
7
Rhythm Pharma Appoints Biotech Veteran Kimberly Popovits to Board, Mathers Resigns
Sentiment: Positive
View Wiseek Article
RYTM
Mar 26, 2026, 4:06 PM EDT
Filing Type: 8-K
Importance Score:
9
Rhythm Pharma's IMCIVREE Receives Positive EU Opinion for Hypothalamic Obesity, Expanding Global Market
Sentiment: Positive
View Wiseek Article
RYTM
Mar 26, 2026, 9:01 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Positive CHMP Opinion for IMCIVREE Expands Rhythm Pharma's European Market Opportunity for Hypothalamic Obesity
Sentiment: Positive
View Wiseek Article
RYTM
Mar 20, 2026, 9:20 AM EDT
Filing Type: 8-K
Importance Score:
9
FDA Approves IMCIVREE for Acquired Hypothalamic Obesity, Expanding Market for First-Ever Therapy
Sentiment: Positive
View Wiseek Article
RYTM
Mar 19, 2026, 6:30 PM EDT
Source: GlobeNewswire
Importance Score:
9
FDA Approves IMCIVREE for Acquired Hypothalamic Obesity, First & Only Therapy for Rare Disease
Sentiment: Positive
View Wiseek Article
RYTM
Mar 16, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
8
Rhythm Pharma's Setmelanotide Phase 3 EMANATE Trial Misses Primary Endpoints, Post Hoc Data Shows Promise
Sentiment: Negative
View Wiseek Article
RYTM
Mar 02, 2026, 6:01 AM EST
Filing Type: 8-K
Importance Score:
8
Rhythm Pharma Reports Strong Additional Phase 3 Data for Setmelanotide in Hypothalamic Obesity Ahead of PDUFA Date
Sentiment: Positive
View Wiseek Article
RYTM
Mar 01, 2026, 12:31 PM EST
Source: Reuters
Importance Score:
9
Setmelanotide Phase 3 Trial Hits Primary Endpoint with 16.4% BMI Reduction; PDUFA Date Set for March 20
Sentiment: Positive
View Wiseek Article
RYTM
Mar 01, 2026, 12:30 PM EST
Source: GlobeNewswire
Importance Score:
9
Expanded Phase 3 Data for Setmelanotide Reveals 18.8% BMI Reduction in Hypothalamic Obesity
Sentiment: Positive
View Wiseek Article
RYTM
Feb 26, 2026, 6:11 PM EST
Source: Reuters
Importance Score:
7
Rhythm Pharmaceuticals Files For Mixed Shelf
Sentiment: Negative
View Wiseek Article